124 related articles for article (PubMed ID: 28190751)
1. Expression of the stem cell marker CD133 is related to tumor development in colorectal carcinogenesis.
Kazama S; Kishikawa J; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Watanabe T
Asian J Surg; 2018 May; 41(3):274-278. PubMed ID: 28190751
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma.
Lee YM; Yeo MK; Seong IO; Kim KH
Anticancer Res; 2018 Aug; 38(8):4819-4826. PubMed ID: 30061254
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Expression of CD133 and LGR5 in Ulcerative Colitis-associated Colorectal Cancer and Dysplasia.
Kazama S; Kishikawa J; Tanaka T; Hata K; Kawai K; Nozawa H; Ishihara S
In Vivo; 2019; 33(4):1279-1284. PubMed ID: 31280219
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
6. The stem cell marker CD133 is highly expressed in sessile serrated adenoma and its borderline variant compared with hyperplastic polyp.
Mohammadi M; Bzorek M; Bonde JH; Nielsen HJ; Holck S
J Clin Pathol; 2013 May; 66(5):403-8. PubMed ID: 23436931
[TBL] [Abstract][Full Text] [Related]
7. High expression of CD133 - stem cell marker for prediction of clinically agressive type of colorectal cancer.
Kostovski O; Antovic S; Trajkovski G; Kostovska I; Jovanovic R; Jankulovski N
Pol Przegl Chir; 2020 Apr; 92(3):9-14. PubMed ID: 32759397
[TBL] [Abstract][Full Text] [Related]
8. Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater.
Piscuoglio S; Lehmann FS; Zlobec I; Tornillo L; Dietmaier W; Hartmann A; Wünsch PH; Sessa F; Rümmele P; Baumhoer D; Terracciano LM
J Clin Pathol; 2012 Feb; 65(2):140-5. PubMed ID: 22130902
[TBL] [Abstract][Full Text] [Related]
9. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
12. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
13. CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis.
Kishikawa J; Kazama S; Oba K; Hasegawa K; Anzai H; Harada Y; Abe H; Matsusaka K; Hongo K; Oba M; Yasuda K; Otani K; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Hata K; Kawai K; Nozawa H; Yamaguchi H; Ishihara S; Sunami E; Ushiku T; Kitayama J; Fukayama M; Kokudo N; Watanabe T
Ann Surg Oncol; 2016 Jun; 23(6):1916-23. PubMed ID: 26832881
[TBL] [Abstract][Full Text] [Related]
14. Aldehyde oxidase 1 promoted the occurrence and development of colorectal cancer by up-regulation of expression of CD133.
Zhang W; Chai W; Zhu Z; Li X
Int Immunopharmacol; 2020 Aug; 85():106618. PubMed ID: 32470878
[TBL] [Abstract][Full Text] [Related]
15. Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer.
Pradhan T; Padmanabhan K; Prasad M; Chandramohan K; Nair SA
J Cell Mol Med; 2019 Jun; 23(6):3984-3994. PubMed ID: 30950180
[TBL] [Abstract][Full Text] [Related]
16. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.
Huang R; Mo D; Wu J; Ai H; Lu Y
Medicine (Baltimore); 2018 Jun; 97(23):e10446. PubMed ID: 29879012
[TBL] [Abstract][Full Text] [Related]
17. CD133 marks for colorectal adenocarcinoma.
Chew MF; Teoh KH; Cheah PL
Malays J Pathol; 2012 Jun; 34(1):25-8. PubMed ID: 22870594
[TBL] [Abstract][Full Text] [Related]
18. PTEN expression in colorectal adenomas: relationship to morphology and cell heterogeneity.
Bendib M; Badescu A; Handra-Luca A
Pathol Res Pract; 2015 Mar; 211(3):248-51. PubMed ID: 25596996
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma.
Park YY; An CH; Oh ST; Chang ED; Lee J
Medicine (Baltimore); 2019 Aug; 98(32):e16709. PubMed ID: 31393377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
